- Home
- DRIO vs TPST Comparison
DRIO vs TPST Comparison
Compare DRIO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- TPST
- Stock Information
- Founded
- DRIO 2011
- TPST 2011
- Country
- DRIO United States
- TPST United States
- Employees
- DRIO N/A
- TPST N/A
- Industry
- DRIO Medical/Dental Instruments
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- DRIO Health Care
- TPST Health Care
- Exchange
- DRIO Nasdaq
- TPST Nasdaq
- Market Cap
- DRIO 30.5M
- TPST 33.0M
- IPO Year
- DRIO N/A
- TPST N/A
- Fundamental
- Price
- DRIO $0.57
- TPST $7.42
- Analyst Decision
- DRIO Strong Buy
- TPST Hold
- Analyst Count
- DRIO 2
- TPST 3
- Target Price
- DRIO $2.50
- TPST $30.00
- AVG Volume (30 Days)
- DRIO 142.8K
- TPST 94.5K
- Earning Date
- DRIO 08-07-2025
- TPST 08-07-2025
- Dividend Yield
- DRIO N/A
- TPST N/A
- EPS Growth
- DRIO N/A
- TPST N/A
- EPS
- DRIO N/A
- TPST N/A
- Revenue
- DRIO $28,034,000.00
- TPST N/A
- Revenue This Year
- DRIO $20.85
- TPST N/A
- Revenue Next Year
- DRIO $17.09
- TPST N/A
- P/E Ratio
- DRIO N/A
- TPST N/A
- Revenue Growth
- DRIO 47.20
- TPST N/A
- 52 Week Low
- DRIO $0.50
- TPST $5.35
- 52 Week High
- DRIO $1.55
- TPST $28.34
- Technical
- Relative Strength Index (RSI)
- DRIO 22.87
- TPST 59.30
- Support Level
- DRIO $0.65
- TPST $7.13
- Resistance Level
- DRIO $0.74
- TPST $8.75
- Average True Range (ATR)
- DRIO 0.05
- TPST 0.45
- MACD
- DRIO -0.01
- TPST 0.13
- Stochastic Oscillator
- DRIO 11.36
- TPST 63.83
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.